This is a proof of concept clinical trial to compare daily intake of at least 20 grams of whole dairy fat vs habitual diet on hepatic steatosis in children with NAFLD.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children, estimated to be present in 5-10% of all children in the United States. NAFLD is a growing cause of cirrhosis and liver cancer. There is not yet an FDA approved treatment for NAFLD. Guidelines recommend improvement in diet at the first line of treatment; however, there is no consensus as to what that diet should be. General health guidelines recommend nonfat or low fat dairy over whole dairy after age 2. Limited studies have suggested that whole dairy may be better for people with NAFLD. This study will test the effect of whole dairy on liver fat in children age 10-17 with NAFLD. As a baseline, the investigators will measure liver fat (using MRI) at 2 time points separated by 12 weeks to establish the current amount of liver fat. The children will be instructed to incorporate 2 ½ servings of whole dairy (as milk and/or yogurt provided by the study will provide) into their daily diet. After 12 weeks, the investigators will measure liver fat with MR and labs to assess safety and further evaluate the liver.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
2 1/2 servings of whole dairy per day
UC San Diego
La Jolla, California, United States
Change in hepatic steatosis measured by liver MRI-PDFF
The primary outcome for the 24 week study is to compare daily intake of at least 20 grams of whole dairy fat vs habitual diet on hepatic steatosis in children with NAFLD
Time frame: Baseline to 12 weeks and 12 weeks to 24 weeks
Change in serum alanine transaminase (ALT)
ALT will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in serum aspartate transaminase (AST)
AST will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in serum gamma-glutamyl transpeptidase (GGT)
GGT will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in serum total cholesterol
Serum total cholesterol will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in serum LDL-cholesterol
Serum LDL-cholesterol will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in serum HDL-cholesterol
Serum HDL-cholesterol will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in serum triglycerides
Serum triglycerides will be measured and compared
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, week 12 and week 24
Change in plasma fatty acid levels
Plasma fatty acid levels will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in subcutaneous adipose tissue (SCAT)
SCAT will be measured and compared
Time frame: Baseline, week 12 and week 24
Change in visceral adipose tissue (VAT)
VAT will be measured and compared
Time frame: Baseline, week 12 and week 24